UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Cancer science, 2021-07, Vol.112 (7), p.2845-2854

2021

Volltextzugriff (PDF)

The clonal evolution during long-term clinical course of multiple myeloma

International journal of hematology, 2021-02, Vol.113 (2), p.279-284

2021

Volltextzugriff (PDF)

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia

Cancer science, 2022-06, Vol.113 (6), p.2085-2096

2022

Volltextzugriff (PDF)

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

International journal of hematology, 2021-03, Vol.113 (3), p.370-380

2021

Volltextzugriff (PDF)

Repeated Intravenous Methylprednisolone May Prevent Deterioration of Hypertrophic Pachymeningitis in Rosai-Dorfman Disease

Internal Medicine, 2024, pp.3884-24

2024

Volltextzugriff (PDF)

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

Cancer science, 2021-06, Vol.112 (6), p.2426-2435

2021

Volltextzugriff (PDF)

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Japanese journal of clinical oncology, 2020-11, Vol.50 (11), p.1265-1273

2020

Volltextzugriff (PDF)

EL28Recent Advances in Therapeutics for Malignant Lymphoma

Annals of oncology, 2019-10, Vol.30 (Supplement_6)

Terui, Yasuhito

2019

Volltextzugriff (PDF)

Recent Advances in Therapeutics for Malignant Lymphoma

Annals of oncology, 2019-10, Vol.30, p.vi63

Terui, Yasuhito

2019

Volltextzugriff (PDF)

Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study

International journal of hematology, 2020-04, Vol.111 (4), p.567-573

2020

Volltextzugriff (PDF)

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

International journal of hematology, 2020-03, Vol.111 (3), p.409-416

2020

Volltextzugriff (PDF)

Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report

Journal of medical case reports, 2024-08, Vol.18 (1), p.372-5

2024

Volltextzugriff (PDF)

Effective collaboration between hematologists and cardiologists facilitated successful control of reversible dasatinib-related pulmonary arterial hypertension and treatment-free remission of chronic myeloid leukemia: a case report

International cancer conference journal, 2022-04, Vol.11 (2), p.142-146

2022

Volltextzugriff (PDF)

Villous colonization (glove balloon sign): A histopathological diagnostic marker for follicular lymphomas with duodenal involvement including duodenal‐type follicular lymphoma

Pathology international, 2019-01, Vol.69 (1), p.48-50

2019

Volltextzugriff (PDF)

Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis

International journal of hematology, 2020, Vol.111 (1), p.103-111

2020

Volltextzugriff (PDF)

Guideline for Management of Febrile Neutropenia 2012 in Jsmo

Annals of oncology, 2014-10, Vol.25, p.v42

Terui, Yasuhito

2014

Volltextzugriff (PDF)

I. Basic Approach for Symptoms and Diagnosis of Malignant Lymphoma ～When and How

Nihon Naika Gakkai Zasshi, 2021/07/10, Vol.110(7), pp.1386-1391

2021

Volltextzugriff (PDF)

Recent Advances in Therapeutics for B-Cell Lymphoma

Journal of pharmacy and pharmacology (El Monte), 2018-01, Vol.6 (1), p.10-19

Yasuhito Terui

2018

Volltextzugriff (PDF)

Abstract A136: KDM5A activity inhibition by 2-PCPA: overcoming tolerance to bortezomib

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A136-A136

2018

Volltextzugriff (PDF)

Abstract A015: Intrapatient heterogeneity of multiple myeloma is evenly distributed in multiple myeloma lesions

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A015-A015

2018

Volltextzugriff (PDF)

Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.4472-4472

2023

Volltextzugriff (PDF)

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Blood, 2023-11, Vol.142 (Supplement 1), p.4464-4464

2023

Volltextzugriff (PDF)

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.6624-6624

2023

Volltextzugriff (PDF)

Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7548-7548

2023

Volltextzugriff (PDF)

Abstract B195: Serum levels of CXCL10 and CXCL11 elevate after skin rash induction, the commonest adverse event by bendamustine in the treatment of malignant lymphoma

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B195-B195

2015

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(157)
Berichte
(2)

Sprache

Englisch
(153)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

The clonal evolution during long-term clinical course of multiple myeloma

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Repeated Intravenous Methylprednisolone May Prevent Deterioration of Hypertrophic Pachymeningitis in Rosai-Dorfman Disease

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

EL28Recent Advances in Therapeutics for Malignant Lymphoma

Recent Advances in Therapeutics for Malignant Lymphoma

Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report

Effective collaboration between hematologists and cardiologists facilitated successful control of reversible dasatinib-related pulmonary arterial hypertension and treatment-free remission of chronic myeloid leukemia: a case report

Villous colonization (glove balloon sign): A histopathological diagnostic marker for follicular lymphomas with duodenal involvement including duodenal‐type follicular lymphoma

Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis

Guideline for Management of Febrile Neutropenia 2012 in Jsmo

I. Basic Approach for Symptoms and Diagnosis of Malignant Lymphoma ～When and How

Recent Advances in Therapeutics for B-Cell Lymphoma

Abstract A136: KDM5A activity inhibition by 2-PCPA: overcoming tolerance to bortezomib

Abstract A015: Intrapatient heterogeneity of multiple myeloma is evenly distributed in multiple myeloma lesions

Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

Abstract B195: Serum levels of CXCL10 and CXCL11 elevate after skin rash induction, the commonest adverse event by bendamustine in the treatment of malignant lymphoma

Aktive Filter

Suchergebnisse filtern